| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $6.0M | — | +531.6% |
| SG&A Expense | $4.4M | — | +219.9% |
| Operating Income | -$10.7M | — | -365.3% |
| Net Income | -$9.6M | — | -330.5% |
| EPS (Basic) | -$0.05 | — | +89.4% |
| EPS (Diluted) | -$0.05 | — | +89.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $132.6M | -0.6% | +1734.4% |
| Current Assets | $133.2M | -0.7% | +1589.4% |
| Total Assets | $133.3M | -0.8% | +1527.8% |
| Current Liabilities | $5.6M | +21.2% | +102.4% |
| Total Liabilities | $6.0M | +19.9% | +108.2% |
| Stockholders' Equity | $127.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.9M | — | -66.7% |
| Financing Cash Flow | $3.1M | — | +1314.3% |
| +2289.1% |